Advanced

Assessing the value of cancer treatments from real world data-Issues, empirical examples and lessons learnt

Moen, F.; Svensson, J. LU and Steen Carlsson, K. LU (2017) In Journal of Cancer Policy 11. p.32-37
Abstract

There is an increasing demand for real world evidence. The shift towards relative effectiveness assessment increasingly based on real world data is a natural consequence of the shift towards new adaptive pathways for development and introduction of new medicines in cancer care. The increasing number of alternative treatment options will further increase the need for outcomes data to help optimize the clinical pathways and resource allocation. In this article the authors explore the opportunities and challenges of real world evidence based on three case studies in cancer care. The central theme is to identify what knowledge gaps can be filled by real world data. Three areas of utility are identified: (1) to validate surrogate endpoints... (More)

There is an increasing demand for real world evidence. The shift towards relative effectiveness assessment increasingly based on real world data is a natural consequence of the shift towards new adaptive pathways for development and introduction of new medicines in cancer care. The increasing number of alternative treatment options will further increase the need for outcomes data to help optimize the clinical pathways and resource allocation. In this article the authors explore the opportunities and challenges of real world evidence based on three case studies in cancer care. The central theme is to identify what knowledge gaps can be filled by real world data. Three areas of utility are identified: (1) to validate surrogate endpoints impact against hard endpoints and outcomes over time; (2) to valuate new treatments outside the strict protocol of clinical trials and (3) to optimize the value of new treatments based on regional variations in uptake. The authors also reflect upon how to increase the availability of real-world evidence and ensure sustainable access to needed data. European collaboration could be part of the solution.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Chronic myeloid leukemia, Prostate cancer, Real world data, Real world evidence, Regional variations, Sustainability, Value of medicines
in
Journal of Cancer Policy
volume
11
pages
32 - 37
publisher
Elsevier
external identifiers
  • scopus:85007481099
ISSN
2213-5383
DOI
10.1016/j.jcpo.2016.11.001
language
English
LU publication?
no
id
018b398f-0bfd-41b5-8687-4272279f4544
date added to LUP
2017-01-17 14:28:04
date last changed
2018-01-07 11:45:20
@article{018b398f-0bfd-41b5-8687-4272279f4544,
  abstract     = {<p>There is an increasing demand for real world evidence. The shift towards relative effectiveness assessment increasingly based on real world data is a natural consequence of the shift towards new adaptive pathways for development and introduction of new medicines in cancer care. The increasing number of alternative treatment options will further increase the need for outcomes data to help optimize the clinical pathways and resource allocation. In this article the authors explore the opportunities and challenges of real world evidence based on three case studies in cancer care. The central theme is to identify what knowledge gaps can be filled by real world data. Three areas of utility are identified: (1) to validate surrogate endpoints impact against hard endpoints and outcomes over time; (2) to valuate new treatments outside the strict protocol of clinical trials and (3) to optimize the value of new treatments based on regional variations in uptake. The authors also reflect upon how to increase the availability of real-world evidence and ensure sustainable access to needed data. European collaboration could be part of the solution.</p>},
  author       = {Moen, F. and Svensson, J. and Steen Carlsson, K.},
  issn         = {2213-5383},
  keyword      = {Chronic myeloid leukemia,Prostate cancer,Real world data,Real world evidence,Regional variations,Sustainability,Value of medicines},
  language     = {eng},
  pages        = {32--37},
  publisher    = {Elsevier},
  series       = {Journal of Cancer Policy},
  title        = {Assessing the value of cancer treatments from real world data-Issues, empirical examples and lessons learnt},
  url          = {http://dx.doi.org/10.1016/j.jcpo.2016.11.001},
  volume       = {11},
  year         = {2017},
}